StockData
Pacira BioSciences, Inc. logo

Pacira BioSciences, Inc. (PCRX) stock

PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3028% above fair value
$36.48+0.00 (0.00%)

Close on Nov 17, 2026Market cap $1.45BP/E 104.2Yield –

Pacira BioSciences operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Pacira BioSciences's operating cash flow for the twelve months ending Jun 30, 2026 was $187.66M, up 39.5% year over year. For fiscal 2025 it was $151.99M, down 19.7% from the year before. Over ten years it grew 18.4% a year on average. The highest annual figure on record is $189.39M in fiscal 2024.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$151.99M-19.7%
FY2024Dec 31, 2024$189.39M+22.5%
FY2023Dec 31, 2023$154.65M+6.5%
FY2022Dec 31, 2022$145.27M+15.6%
FY2021Dec 31, 2021$125.72M+63.2%
FY2020Dec 31, 2020$77.03M+9.2%
FY2019Dec 31, 2019$70.52M+44.3%
FY2018Dec 31, 2018$48.87M+174.8%
FY2017Dec 31, 2017$17.79M-46.8%
FY2016Dec 31, 2016$33.45M+19.4%
FY2015Dec 31, 2015$28.02M+5.5%
FY2014Dec 31, 2014$26.56M–
FY2013Dec 31, 2013-$43.84M–
FY2012Dec 31, 2012-$70.13M–
FY2011Dec 31, 2011-$31.00M–
FY2010Dec 31, 2010-$24.88M–
FY2009Dec 31, 2009-$20.84M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$57.46M+378.4%
Q1 FY2026Mar 31, 2026$25.68M-27.6%
Q4 FY2025Dec 31, 2025$43.69M+31.9%
Q3 FY2025Sep 30, 2025$60.83M+12.8%
Q2 FY2025Jun 30, 2025$12.01M-77.4%
Q1 FY2025Mar 31, 2025$35.46M-27.8%
Q4 FY2024Dec 31, 2024$33.13M-30.4%
Q3 FY2024Sep 30, 2024$53.92M+21.3%
Q2 FY2024Jun 30, 2024$53.24M+22.4%
Q1 FY2024Mar 31, 2024$49.10M+156.7%
Q4 FY2023Dec 31, 2023$47.58M+13.2%
Q3 FY2023Sep 30, 2023$44.44M+4.2%
Q2 FY2023Jun 30, 2023$43.50M+45.9%
Q1 FY2023Mar 31, 2023$19.13M-37.8%
Q4 FY2022Dec 31, 2022$42.04M+81.1%
Q3 FY2022Sep 30, 2022$42.65M-29.2%
Q2 FY2022Jun 30, 2022$29.81M-1.1%
Q1 FY2022Mar 31, 2022$30.78M+154.8%
Q4 FY2021Dec 31, 2021$23.22M-50.3%
Q3 FY2021Sep 30, 2021$60.29M+51.5%
Q2 FY2021Jun 30, 2021$30.13M–
Q1 FY2021Mar 31, 2021$12.08M+94.6%
Q4 FY2020Dec 31, 2020$46.67M+80.2%
Q3 FY2020Sep 30, 2020$39.78M+116.7%
Q2 FY2020Jun 30, 2020-$15.62M-168.6%
Q1 FY2020Mar 31, 2020$6.21M+77.4%
Q4 FY2019Dec 31, 2019$25.90M+22.1%
Q3 FY2019Sep 30, 2019$18.35M+10.4%
Q2 FY2019Jun 30, 2019$22.76M+66.0%
Q1 FY2019Mar 31, 2019$3.50M–
Q4 FY2018Dec 31, 2018$21.22M+25.3%
Q3 FY2018Sep 30, 2018$16.63M–
Q2 FY2018Jun 30, 2018$13.71M+275.0%
Q1 FY2018Mar 31, 2018-$2.69M-44916.7%
Q4 FY2017Dec 31, 2017$16.93M-2.4%
Q3 FY2017Sep 30, 2017-$2.81M-124.0%
Q2 FY2017Jun 30, 2017$3.66M–
Q1 FY2017Mar 31, 2017$6.00K–
Q4 FY2016Dec 31, 2016$17.35M–
Q3 FY2016Sep 30, 2016$11.68M–

More Pacira BioSciences figures

See a number that looks wrong?